Spearhead Bio has closed an oversubscribed $1.62 million seed round to scale a genome engineering platform that tackles one of CRISPR's hardest problems in crop breeding: inserting or replacing large pieces of DNA at precise locations in plant genomes.

The St. Louis-based company launched out of Danforth Technology Company (DTC), a subsidiary of the Donald Danforth Plant Science Center, roughly two years before the raise. BioGenerator Ventures and DTC led the round, with participation from QRM Capital, Grit Road Partners, the St. Louis Port Authority Helix Fund, SDH Capital and other investors.

What does TAHITI change for crop developers?

The company's platform, Transposase Assisted Homology Independent Targeted Insertion (TAHITI), fuses a transposable element directly to Cas9 or Cas12a — CRISPR's molecular scissors. When CRISPR cuts the genome, TAHITI glues new genetic cargo into that break precisely.

CEO Mike Bielski frames the problem in plain terms: CRISPR can replace single letters — turning "wood" into "food" — but cannot add or move whole sentences. Conventional editing inserts new material at random, which can disrupt other genes and complicate downstream breeding.

"We happen to use CRISPR, but the platform is really about transposable elements and what transposable elements can do with these large DNA cargo movements," Bielski said.

Founder Keith Slotkin calls transposable elements "nature's own gene-editing machinery" and "the glue that works with CRISPR scissors to create a better toolbox." In nature, these elements rearrange genomes randomly over thousands or millions of years; TAHITI puts breeders in control of that process.

How does this hit seed company margins?

The economics are the pitch. Slotkin claims seed companies today run enormous pipelines because editing efficiency sits below 1%, forcing them to screen vast numbers of plants to find a desired rearrangement. TAHITI, he says, raises that efficiency so partners find target edits far faster.

"It saves our partners years of development time and millions of dollars in crop improvement," Slotkin said.

The regulatory angle may matter more. TAHITI works in both transgenic (GMO) and non-transgenic applications. For non-transgenic edits, companies can pursue faster, cheaper regulatory pathways. Slotkin estimates the difference: instead of an additional three years and $80 million to move a trait through deregulation, the process should be "much faster."

That figure is a company claim, not an audited cost benchmark, and actual savings will depend on how regulators in each export market treat large DNA replacements made with transposable elements.

Which crops and partners are first in line?

Spearhead Bio is in "active discussions" with industry partners, with technical milestones as the main near-term focus. The current work centers on soybean.

"What we really want to do is create products for companies — traits — and so we're working with them on, for example, the soybean transposable element," Slotkin said.

The company is now pushing beyond insertion into simultaneous replacement — deleting a gene segment while adding new DNA at the same location. "The net balance there is that we're performing replacements without introducing foreign DNA in a crop genome like soybean with industry partners," Slotkin said.

Bielski says the platform opens edits that the current toolbox cannot deliver: "There are so many different things you can do when you have the ability to precisely move large pieces of DNA to where you want them. It's everything from stacking traits to complete replacement of genes."

Why investors crowded into the round

Spearhead Bio is the third company spun out of DTC, and DTC CEO Tom Laurita calls it possibly "the most impactful new technology to come out of the Danforth Center."

Fundraising was not immediate, Bielski acknowledged, but the Danforth Center affiliation and a clear separation from the crowded CRISPR field helped. "The ability to articulate to people that we weren't just another CRISPR company, and getting people to understand how disruptive this could be, made the fundraising a little more straightforward," he said. "We wound up being oversubscribed at the end."

With the $1.62 million in hand, Spearhead Bio's next test is hitting its technical milestones in soybean and converting partner discussions into trait-development deals.